Literature DB >> 26418904

Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.

Alessandra Farchione1, Vittoria Rufini, Maria Gabriella Brizi, Donato Iacovazzo, Alberto Larghi, Roberto Maria Massara, Gianluigi Petrone, Andrea Poscia, Giorgio Treglia, Laura De Marinis, Alessandro Giordano, Guido Rindi, Lorenzo Bonomo.   

Abstract

OBJECTIVES: The aims of this study were to investigate the added value of diffusion-weighted imaging (DWI) in pancreatic neuroendocrine tumor (pNET) evaluation and to compare magnetic resonance imaging (MRI) to Ga-DOTANOC positron emission tomography/computed tomography (PET/CT) results.
METHODS: Morphological MRI (T2-weighted [T2-w] + contrast-enhanced [CE] T1-w) and DWI (T2-w + DWI) and Ga-DOTANOC PET/CT in 25 patients/30 pNETs were retrospectively evaluated. Per-patient and per-lesion detection rates (pDR and lDR, respectively) were calculated. Apparent diffusion coefficient values were compared among pNET and surrounding and normal pancreas (control group, 18 patients). Apparent diffusion coefficient and standardized uptake value (SUV) values were compared among different grading and staging groups.
RESULTS: No statistically significant differences in PET/CT and MRI session detection rates were found (morphological MRI and DW-MRI, 88% pDR and 87% lDR; combined evaluation, 92% pDR and 90% lDR; Ga-DOTANOC PET/CT, 88% pDR and 80% lDR). Consensus reading (morphological/DW-MRI + PET/CT) improved pDR and lDR (100%). Apparent diffusion coefficient mean value was significantly lower compared with surrounding and normal parenchyma (P < 0.01). The apparent diffusion coefficient and SUV values of pNETs among different grading and staging groups were not statistically different.
CONCLUSIONS: Conventional MRI, DW-MRI + T2-w sequences, and Ga-DOTANOC PET/CT can be alternative tools in pNET detection. Diffusion-weighted MRI could be valuable in patients with clinical suspicion but negative conventional imaging findings. However, the consensus reading of the 3 techniques seems the best approach.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26418904     DOI: 10.1097/MPA.0000000000000461

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

Review 1.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 2.  Rectal neuroendocrine neoplasms: what the radiologists should know.

Authors:  Mayur Virarkar; Dheeraj R Gopireddy; Ajaykumar C Morani; Ahmad Alkhasawneh; Sergio Piotr Klimkowski; Sindhu Kumar; Chandana Lall; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2022-03-14

Review 3.  Gastric neuroendocrine neoplasms: a primer for radiologists.

Authors:  Molly E Roseland; Isaac R Francis; Kimberly L Shampain; Erica B Stein; Ashish P Wasnik; John D Millet
Journal:  Abdom Radiol (NY)       Date:  2022-04-12

Review 4.  [Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics].

Authors:  J Rübenthaler; C Auernhammer; I Harun; J Ricke; C C Cyran
Journal:  Radiologe       Date:  2019-11       Impact factor: 0.635

5.  PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?

Authors:  Ali Pirasteh; Christopher Riedl; Marius Erik Mayerhoefer; Romina Grazia Giancipoli; Steven Mark Larson; Lisa Bodei
Journal:  Clin Transl Imaging       Date:  2019-09-20

Review 6.  Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.

Authors:  Ali Pirasteh; Petra Lovrec; Lisa Bodei
Journal:  Rev Endocr Metab Disord       Date:  2021-03-30       Impact factor: 9.306

7.  Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage.

Authors:  Riccardo De Robertis; Sara Cingarlini; Paolo Tinazzi Martini; Silvia Ortolani; Giovanni Butturini; Luca Landoni; Paolo Regi; Roberto Girelli; Paola Capelli; Stefano Gobbo; Giampaolo Tortora; Aldo Scarpa; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

8.  Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.

Authors:  C G Genç; M Falconi; S Partelli; F Muffatti; S van Eeden; C Doglioni; H J Klümpen; C H J van Eijck; E J M Nieveen van Dijkum
Journal:  Ann Surg Oncol       Date:  2018-05-22       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.